NEWARK,
Del., April 30, 2024 /PRNewswire/ -- The
National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from
41 academic institutions have been selected to take part in the
2024 NIIMBL eXperience, the largest cohort since the Program's
launch in 2019. Students will participate in one of five NIIMBL
eXperience programs hosted by Albany College
of Pharmacy and Health Sciences, North
Carolina State University (Biomanufacturing Training and
Education Center), Thomas Jefferson
University (Jefferson Institute for Bioprocessing),
Santa Clara University, and the
University of Houston.
The NIIMBL eXperience is a week-long, all-expenses-paid
immersion program designed to introduce underrepresented groups
including Black, Latinx, and Indigenous students completing their
first or second year of college to career possibilities in the
biopharmaceutical industry. The goal is to increase the diversity
of the school-to-industry pipeline and strengthen the biopharma
workforce of the future.
"The NIIMBL eXperience has been a cornerstone of our efforts to
expand and diversify talent pipelines for the biopharmaceutical
industry," said John Balchunas,
NIIMBL Workforce Director. "We are excited about the continued
growth of the program and look forward to connecting another group
of talented students to the industry."
Since 2019, the NIIMBL eXperience has served 80 students from 69
different academic institutions. Participants have secured
internships and jobs at leading biopharmaceutical companies,
including Merck, MilliporeSigma, Pfizer, and Eli Lilly.
The 2024 NIIMBL eXperience dates are: Albany College of Pharmacy and Health Sciences –
June 2 – 8; North Carolina State University (BTEC) –
June 3-7; Thomas
Jefferson University (JIB) – June
3-7; Santa Clara University –
June 23-29; University of Houston – June
3-7.
For more information and to view the list of student
participants, visit niimbl.org.
About NIIMBL
The National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL) is a public-private partnership whose
mission is to accelerate biopharmaceutical innovation, support the
development of standards that enable more efficient and rapid
manufacturing capabilities, and educate and train a world-leading
biopharmaceutical manufacturing workforce, fundamentally advancing
U.S. competitiveness in this industry. NIIMBL is part of
Manufacturing USA®, a diverse network of federally sponsored
manufacturing innovation institutes, and is funded through a
cooperative agreement with the National Institute of Standards and
Technology (NIST) in the U.S. Department of Commerce with
significant additional support from its members.
Contact:
News Media
Daniel Maiese
Communications Manager
302-831-3824
dmaiese@udel.edu
View original content to download
multimedia:https://www.prnewswire.com/news-releases/niimbl-announces-63-students-for-the-2024-niimbl-experience-302132141.html
SOURCE National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL)